Karolin Streule

Karolin Streule

Auto-generated profile, based on publicly available information

Karolin Streule

Karlsruhe Institute of Technology, Institute of Biological and Chemical Systems-Functional Molecular Systems, Karlsruhe, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2021 in Blood
Verified
Journal Article
Closed access
PDF file
XYXiaobing Yu
Xiaobing Yu
LMLeonel Munoz-Sagredo
Leonel Munoz-Sagredo
KSKarolin Streule
Karolin Streule
PMPatricia Muschong
Patricia Muschong
EBElisabeth Bayer
Elisabeth Bayer
Véronique Orian-RousseauVéronique Orian-Rousseau
Véronique Orian-Rousseau
Acute myeloid leukemia (AML) has a poor prognosis under the current standard of care. In recent years, venetoclax, a BCL-2 inhibitor, was approved to treat patients who are ineligible for intensive induction chemotherapy. However, complete remission rates with venetoclax-based therapies are hampered by minimal residual disease (MRD) in a proportion of patients, leading to relapse. MRD is a result of leukemic stem cells being retained in bone marrow protective environments; activation of the CXCL12-CXCR4 pathway was shown to be relevant to this process. An important role is also played by cell adhesion molecules such as CD44, which has been shown to be crucial for the development of AML. Here we show that CD44 is involved in CXCL12 promotion of resistance to venetoclax-induced apoptosis in human AML cell lines and AML patient samples, which could be abrogated by CD44 knock down, knockout, or blocking with an anti-CD44 antibody. Split-Venus bimolecular fluorescence complementation showed that CD44 and CXCR4 physically associate at the cell membrane upon CXCL12 induction. In the venetoclax-resistant OCI-AML3 cell line, CXCL12 promoted an increase in the proportion of cells expressing high levels of embryonic stem cell core transcription factors (ESC-TFs: Sox2, Oct4, Nanog) abrogated by CD44 knockdown. This ESC-TF–expressing subpopulation which could be selected by venetoclax treatment, exhibited a basally enhanced resistance to apoptosis and expressed higher levels of CD44. Finally, we developed a novel AML xenograft model in zebrafish, which showed that CD44 knockout sensitizes OCI-AML3 cells to venetoclax treatment in vivo. Our study shows that CD44 is a potential molecular target for sensitizing AML cells to venetoclax-based therapies.

26 June 2020 in Bioinformatics
Verified
Journal Article
Open access
PDF file
TSTim Scherr
Tim Scherr
KSKarolin Streule
Karolin Streule
ABAndreas Bartschat
Andreas Bartschat
MBMoritz Böhland
Moritz Böhland
JSJohannes Stegmaier
Johannes Stegmaier
RMRalf Mikut
Ralf Mikut
An automated counting of beads is required for many high-throughput experiments such as studying mimicked bacterial invasion processes. However, state-of-the-art algorithms under- or overestimate the number of beads in low-resolution images. In addition, expert knowledge is needed to adjust parameters. In combination with our image labeling tool, BeadNet enables biologists to easily annotate and process their data reducing the expertise required in many existing image analysis pipelines. BeadNet outperforms state-of-the-art-algorithms in terms of missing, added and total amount of beads. BeadNet (software, code and dataset) is available at https://bitbucket.org/t_scherr/beadnet. The image labeling tool is available at https://bitbucket.org/abartschat/imagelabelingtool. Supplementary data are available at Bioinformatics online.